Worth reading
48Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
8.7
% (year-on-year change in consolidated revenue)Wording
Conditional
How definitive the wording is.Results for this period
Full year1 April 2025–31 March 2026ConsolidatedJapanese GAAPNet Sales241,851¥ millionYear on year +8.7%Progress 92.8%
Operating profit22,454¥ millionYear on year +10.1%Progress 88.4%
Ordinary income25,478¥ millionYear on year +14.4%Progress 101.1%
Net income attributable to owners of the parent24,641¥ millionYear on year +40.7%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥161.18
Operating Margin9.3％
Financial position at period-end
Total assets398,736¥ million
of which net assets 280,104 ¥ millionEquity ratio 70.0%vs. prior year-end -1.6pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating+28,784
Investment-17,184
Financials-20,235
Net change-8,635
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period¥53,368 million
Segment revenueMobility & Imaging business area ¥94,714 million (YoY +3.7%), Fine Chemicals business area ¥74,142 million (YoY +12.0%), Life Sciences business area ¥72,994 million (YoY +12.3%)
Segment profitMobility & Imaging business area ¥10,654 million (YoY -20.0%), Fine Chemicals business area ¥11,929 million (YoY +20.5%), Life Sciences business area ¥9,680 million (YoY +52.3%)
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥260,600 million (YoY +7.8%)
Operating profit¥25,400 million (YoY +13.1%)
Ordinary income¥25,200 million (YoY -1.1%)
Profit attributable to owners of the parent¥22,300 million (YoY -9.5%)
Annual Dividend Forecast¥66 → ¥66（0.0%）
Payout ratio40.9％
Shareholder Return PolicyThe company targets a dividend payout ratio of at least 40% of consolidated net income. It will ensure sufficient retained earnings while flexibly repurchasing treasury shares.
Factors Behind Changes in Business Performance
Revenue increased in all 3 business areas. Fine Chemicals benefited from the expansion of the semiconductor market and other factors, while Life Sciences benefited from the market penetration of new drugs and biosimilars and increased overseas sales of flometoquin. Mobility & Imaging reported lower income due to soaring raw material costs. Ordinary income benefited from foreign exchange gains, while net income was supported by gains on sales of investment securities and other factors.
Disclosure regarding the going concern assumption
Not applicable.
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed
Material subsequent eventsThe company resolved to acquire up to 13,000,000 treasury shares for a maximum of ¥15 billion and to cancel 11,300,000 treasury shares on 22 May 2026.
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of non-current assets 109 / Gain on liquidation of affiliates 120 / Gain on sale of investment securities 9,431 / Total extraordinary income 9,661 / Extraordinary loss Losses on disposal of fixed assets 828 / Impairment loss on investment securities 284 / Special retirement payments 100 / Losses from natural disasters 334 / Total extraordinary loss 1,546
Depreciation and amortization¥15,618 million
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingWhether applicable Yes / Subject person For securities analysts and institutional investors
Issued Shares at Period-End160,000,000 Shares
Treasury Shares at Period-End11,505,220 Shares
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥241,851 million (YoY +8.7%) |
| Operating profit | ¥22,454 million (YoY +10.1%) |
| Ordinary income | ¥25,478 million (YoY +14.4%) |
| Profit attributable to owners of the parent | ¥24,641 million (YoY +40.7%) |
| Net income per share | ¥161.18 |
| Operating Margin | 9.3％ |
| Equity ratio | End of the current fiscal period 70.0％ / End of previous period 71.6％ |
| Total assets | ¥398,736 million |
| Net assets | ¥280,104 million |
| Cash flows from operating activities | ¥28,784 million |
| Cash flows from investing activities | ¥-17,184 million |
| Cash flows from financing activities | ¥-20,235 million |
| Cash and cash equivalents at end of period | ¥53,368 million |
| Full-year earnings forecast | Net Sales ¥260,600 million (YoY +7.8%) / Operating profit ¥25,400 million (YoY +13.1%) / Ordinary income ¥25,200 million (YoY -1.1%) / Profit attributable to owners of the parent ¥22,300 million (YoY -9.5%) |
| Annual Dividend Forecast | ¥66 → ¥66（0.0%） |
| Payout ratio | 40.9％ |
| Shareholder Return Policy | The company targets a dividend payout ratio of at least 40% of consolidated net income. It will ensure sufficient retained earnings while flexibly repurchasing treasury shares. |
| Segment revenue | Mobility & Imaging business area ¥94,714 million (YoY +3.7%), Fine Chemicals business area ¥74,142 million (YoY +12.0%), Life Sciences business area ¥72,994 million (YoY +12.3%) |
| Segment profit | Mobility & Imaging business area ¥10,654 million (YoY -20.0%), Fine Chemicals business area ¥11,929 million (YoY +20.5%), Life Sciences business area ¥9,680 million (YoY +52.3%) |
| Depreciation and amortization | ¥15,618 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets 109 / Gain on liquidation of affiliates 120 / Gain on sale of investment securities 9,431 / Total extraordinary income 9,661 / Extraordinary loss Losses on disposal of fixed assets 828 / Impairment loss on investment securities 284 / Special retirement payments 100 / Losses from natural disasters 334 / Total extraordinary loss 1,546 |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed |
| Material subsequent events | The company resolved to acquire up to 13,000,000 treasury shares for a maximum of ¥15 billion and to cancel 11,300,000 treasury shares on 22 May 2026. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person For securities analysts and institutional investors |
| Issued Shares at Period-End | 160,000,000 Shares |
| Treasury Shares at Period-End | 11,505,220 Shares |
| Factors Behind Changes in Business Performance | Revenue increased in all 3 business areas. Fine Chemicals benefited from the expansion of the semiconductor market and other factors, while Life Sciences benefited from the market penetration of new drugs and biosimilars and increased overseas sales of flometoquin. Mobility & Imaging reported lower income due to soaring raw material costs. Ordinary income benefited from foreign exchange gains, while net income was supported by gains on sales of investment securities and other factors. |
Items this document does not state (4)
Revision to Earnings ForecastRegional salesOrders received and order backlogImpairment loss
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue exceeded the previous fiscal year in all business areas: Mobility & Imaging, Fine Chemicals and Life Sciences. Higher income in Fine Chemicals and Life Sciences contributed to the increase in operating income, while Mobility & Imaging was affected by soaring raw material costs. The increase in ordinary income was attributable to higher foreign exchange gains, while profit attributable to owners of the parent was supported by gains on sales of investment securities and other factors.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.